Fig. 1

Decreased neuronal m6A modification in AD brains. (A-F) Representative immunohistochemical staining (A-B, D-E) and quantifications (C,F) of m6A using two different antibodies [rabbit antibody from SYSY (A, D) and mouse antibody from Novus (B, E)] in hippocampus (Hipp) (A-C) and cortex (CTX) (D-F) from human AD and age-matched control cases. (G-H) Colocalization analysis of m⁶A with neuronal marker MAP 2 in hippocampal tissues from AD and control brains (G) and quantification of neuronal m⁶A immunoreactivity colocalized with MAP 2 was shown (H). (I) Global m⁶A level was measured using total RNA isolated from AD and control frontal cortical tissues by LC-MS/MS. The arrows in inserts (A-G) point to neurons and asterisks indicate glial cells (n = 5–6 cases per group). (Data are means±SEM, *p < 0.05, (C, F, H, I) unpaired student’s t-test)